Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism

Sam Schulman, MD PhD, Henry Eriksson, MD PhD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Patrick Mismetti, MD PhD, Martin Feuring, MD, Stefan Hantel, PhD, Joerg Kreuzer, MD, Samuel Z. Goldhaber, MD

Blood (2014) 124 (21): 4270.

https://doi.org/10.1182/blood.V124.21.4270.4270

Published: 2014

Journal Articles

Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II

Sam Schulman, MD PhD, Henry Eriksson, MD PhD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Patrick Mismetti, MD, Martin Feuring, MD, Stefan Hantel, PhD, Joerg Kreuzer, MD, Samuel Z. Goldhaber, MD

Blood (2014) 124 (21): 594.

https://doi.org/10.1182/blood.V124.21.594.594

Published: 2014

Journal Articles

Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY™

Sam Schulman, MD PhD, Henry Eriksson, MD PhD, Samuel Z. Goldhaber, MD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Martin Feuring, MD, Jeffrey Friedman, MD, Joerg Kreuzer, MD

Blood (2014) 124 (21): 1544.

https://doi.org/10.1182/blood.V124.21.1544.1544

Published: 2014

Journal Articles

Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II

Sam Schulman, MD, PhD, Henry Eriksson, MD, PhD, Samuel Z Goldhaber, MD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Joerg Kreuzer, MD, Nuala Peter, BSc (Hons), Jeffrey Friedman, MD

Blood (2013) 122 (21): 2375.

https://doi.org/10.1182/blood.V122.21.2375.2375

Published: 2013

Journal Articles

Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Sam Schulman, MD, PhD, Henry Eriksson, MD, PhD, Samuel Z Goldhaber, MD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Martin Feuring, MD, Nuala Peter, BSc (Hons), Jeffrey Friedman, MD

Blood (2013) 122 (21): 1136.

https://doi.org/10.1182/blood.V122.21.1136.1136

Published: 2013

Journal Articles

Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Blood (2013) 122 (21): 582.

https://doi.org/10.1182/blood.V122.21.582.582

Published: 2013

Journal Articles

Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Blood (2013) 122 (21): 212.

https://doi.org/10.1182/blood.V122.21.212.212

Published: 2013

Journal Articles

A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)

Sam Schulman, MD, PhD, Ajay K Kakkar, MD, Sebastian M Schellong, MD, Samuel Z. Goldhaber, MD, Eriksson Henry, MD, PhD, Patrick Mismetti, MD, PhD, Anita Vedel Christiansen, MSc.Pharm., Janet Schnee, MD, Clive Kearon, MB, PhD

Blood (2011) 118 (21): 205.

https://doi.org/10.1182/blood.V118.21.205.205

Published: 2011

Journal Articles

Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism.

Sam Schulman, Henry Eriksson, Samuel Z. Goldhaber, Ajay K Kakkar, MD, PhD, Clive Kearon, Patrick Mismetti, Sebastian M Schellong, David Baanstra, Janet Schnee

Blood (2009) 114 (22): 1.

https://doi.org/10.1182/blood.V114.22.1.1

Published: 2009

Journal Articles

Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study

Alexander GG Turpie, MD, Russell D Hull, MBBS, Sebastian M Schellong, MD, Victor F Tapson, MD, Manuel Monreal, MD, Meyer Michel Samama, MD, PharmD, Roger D Yusen, MD, MPH

Blood (2008) 112 (11): 433.

https://doi.org/10.1182/blood.V112.11.433.433

Published: 2008

Journal Articles

The Impact of Age on the Efficacy and Safety of Extended-Duration Thromboprophylaxis in Acutely Ill Medical Patients with Recent Immobility: A Sub-Group Analysis from the EXCLAIM Study

Roger D Yusen, Russell D Hull, Sebastian M Schellong, Victor F Tapson, Manuel Monreal, Michel Meyer Samama, Min Chen, Alexander GG Turpie

Blood (2008) 112 (11): 438.

https://doi.org/10.1182/blood.V112.11.438.438

Published: 2008

Journal Articles

The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.

Frederick A Anderson, Jr., PhD, Russell D Hull, MBBS, Sebastian M Schellong, MD, Bruno Deslandes, Victor F Tapson, MD, Meyer Michel Samama, MD, PharmD, Alexander GG Turpie, MD, Roger D Yusen, MD, MPH, Herve Decousus, MD, Alexander T Cohen, MBBS, MSc, MD, FRACP, Manuel Monreal, MD

Blood (2008) 112 (11): 1981.

https://doi.org/10.1182/blood.V112.11.1981.1981

Published: 2008

Journal Articles

The Effects of the Degree of Mobility Reduction and Prespecified Risk Factors on Venous Thromboembolism Rates in Acutely Ill Medical Patients in the EXCLAIM Study.

Roger D. Yusen, Russell D. Hull, Sebastian M. Schellong, Victor F. Tapson, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie

Blood (2007) 110 (11): 1862.

https://doi.org/10.1182/blood.V110.11.1862.1862

Published: 2007

Journal Articles

Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients in the EXCLAIM Study.

Victor F. Tapson, Russell D. Hull, Sebastian M. Schellong, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie, Roger D. Yusen

Blood (2007) 110 (11): 1863.

https://doi.org/10.1182/blood.V110.11.1863.1863

Published: 2007

Journal Articles

Extended-Duration Enoxaparin for Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients: An Evaluation of the EXCLAIM Study Based on a Recently Recommended Composite Efficacy Endpoint.

Sebastian M. Schellong, Russell D. Hull, Victor F. Tapson, Manuel Monreal, Meyer-Michel Samama, Alexander G.G. Turpie, Roger D. Yusen

Blood (2007) 110 (11): 1870.

https://doi.org/10.1182/blood.V110.11.1870.1870

Published: 2007

Journal Articles

Results of a One-Year Registry of Bleeding Complications of Vitamin K Antagonist Therapy outside of a Controlled Population.

Kai M. Halbritter, Jan Beyer, Wolfram Oettler, Babett Kleinstück, Sebastian M. Schellong

Blood (2006) 108 (11): 4121.

https://doi.org/10.1182/blood.V108.11.4121.4121

Published: 2006

Journal Articles

Interobserver Agreement of Centrally Adjudicated Venous Ultrasound Video Documents in Asymptomatic Patients after Hip and Knee Replacement.

Benjamin A. Schmidt, MD, Matthias Guenther, Kai Halbritter, MD, Jan Beyer, MD, Sebastian M. Schellong, MD

Blood (2005) 106 (11): 3208.

https://doi.org/10.1182/blood.V106.11.3208.3208

Published: 2005

Journal Articles

VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.

Sebastian M. Schellong, MD, Jan Beyer, MD, Kai Halbritter, MD, Benjamin Schmidt, MD, Alexander G.G. Turpie, MD, Bengt I. Eriksson, MD, PhD, Frank Misselwitz, MD, PhD, Peter Kälebo, MD

Blood (2005) 106 (11): 281.

https://doi.org/10.1182/blood.V106.11.281.281

Published: 2005

NARROW

Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism

Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II

Influence of Thrombophilia on the Efficacy of Dabigatran Versus Warfarin for the Extended Treatment of Acute Venous Thromboembolism in RE-MEDY™

Influence Of Age On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis Of RE-Cover and RE-Cover II

Influence Of Concomitant NSAID Or ASA On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Influence Of Renal Function On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

A Randomized Trial of Dabigatran Versus Warfarin in the Treatment of Acute Venous Thromboembolism (RE-COVER II)

Dabigatran Etexilate Versus Warfarin in the Treatment of Venous Thromboembolism.

Venous Thromboembolism Risk in Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Sub-Analysis of the EXCLAIM Study

The Impact of Age on the Efficacy and Safety of Extended-Duration Thromboprophylaxis in Acutely Ill Medical Patients with Recent Immobility: A Sub-Group Analysis from the EXCLAIM Study

The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.

The Effects of the Degree of Mobility Reduction and Prespecified Risk Factors on Venous Thromboembolism Rates in Acutely Ill Medical Patients in the EXCLAIM Study.

Consistent Venous Thromboembolism Risk Reduction by Extended- Versus Standard-Duration Enoxaparin Prophylaxis in Subgroups of Acutely Ill Medical Patients in the EXCLAIM Study.

Extended-Duration Enoxaparin for Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients: An Evaluation of the EXCLAIM Study Based on a Recently Recommended Composite Efficacy Endpoint.

Results of a One-Year Registry of Bleeding Complications of Vitamin K Antagonist Therapy outside of a Controlled Population.

Interobserver Agreement of Centrally Adjudicated Venous Ultrasound Video Documents in Asymptomatic Patients after Hip and Knee Replacement.

VENUS - A Study To Validate Centrally Adjudicated Venous Ultrasound Against Venography after Major Orthopaedic Surgery.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only